

Cover Story
By Matthew Bin Han Ong
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- With Anthony Letai’s appointment, NCI is now under new leadership—just in time for a shutdown
- Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research
- Anthony Letai sworn in as 18th NCI director
- U.S. government shuts down
Impact on NCI uncertain as administration threatens more RIFs - Former NCI official’s nonprofit seeks to tell the stories of cancer patients
Patient Action for Cancer Research aims to show impact of federal research - Sakaguchi, Ramsdell, Rudensky win Crafoord Prize for discoveries in immune regulation